Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CDC25A | P30304 | 10/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.50 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15923132 | 0.94 | CES1 (0.57) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL15923211 | 0.94 | CES1 (0.57) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL15923122 | 0.94 | CES1 (0.57) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL21318441 | 0.94 | CES1 (0.57) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL15923015 | 0.91 | TDP1 (0.54) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL15923416 | 0.91 | TDP1 (0.54) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL10725626 | 0.91 | MAPT (0.58) | MAPTRAB9ASMN1; SMN2CDC25ACES1 | |
| SCHEMBL28203937 | 0.88 | HPGD (0.51) | MAPTRAB9ASMN1; SMN2CDC25ACES1 | |
| SCHEMBL31197405 | 0.88 | HPGD (0.51) | MAPTRAB9ASMN1; SMN2CDC25ACES1 | |
| SCHEMBL23731163 | 0.85 | CES1 (0.68) | TDP1L3MBTL1CDC25ACES1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163476-A1 | IMIDAZOQUINOLYL COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2021-06-03 | — | — | US | disclosed |
| US-10934284-B2 | Aminoquinazoline compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | WELLSTAT THERAPEUTICS CORPORATION (US) | 2021-03-02 | — | — | US | disclosed |
| EP-3632426-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | Wellstat Therapeutics Corporation (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-2950649-B1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | WELLSTAT THERAPEUTICS CORP (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20190194193-A1 | AMINOQUINAZOLINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2019-06-27 | — | — | US | disclosed |
| US-20180298000-A1 | AMINOQUINOLINE COMPOUNDS HAVING ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2018-10-18 | — | — | US | disclosed |
| US-20150361077-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | PHARMA CINQ, LLC | 2015-12-17 | — | — | US | disclosed |
| EP-2950649-A2 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | Wellstat Therapeutics Corporation (US) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014120995-A2 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC AND ANTICANCER ACTIVITY | WELLSTAT THERAPEUTICS CORPORATION (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163476-A1 | IMIDAZOQUINOLYL COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | NOD1, NLRP3, AADAC | TDP1 3015/4885L3MBTL1 1523/4885MAPT 2848/4885 |
| US-20180298000-A1 | AMINOQUINOLINE COMPOUNDS HAVING ANTICANCER ACTIVITY | MYC, AAAS, ASNS | TDP1 2901/4885L3MBTL1 2202/4885MAPT 2107/4885 |
| US-20190194193-A1 | AMINOQUINAZOLINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | AAAS, AADAC, NFKBIA | TDP1 2433/4885L3MBTL1 2833/4885MAPT 2661/4885 |
| US-20150361077-A1 | AMINE COMPOUNDS HAVING ANTI-INFLAMMATORY, ANTIFUNGAL, ANTIPARASITIC, AND ANTICANCER ACTIVITY | AADAC, CASP1, AAAS | TDP1 2102/4885L3MBTL1 1868/4885MAPT 1131/4885 |
| US-10934284-B2 | Aminoquinazoline compounds having anti-inflammatory, antifungal, antiparasitic, and anticancer activity | AAAS, AADAC, NFKBIA | TDP1 2433/4885L3MBTL1 2833/4885MAPT 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.